



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria. Virginia 22313-1450 www.nspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/723,703	11/28/2000	David Botstein	P2533C2	7610
9157	7590 08/18/2004		EXAMINER	
GENENTEC	H, INC.		HELMS, LAR	RY RONALD
I DNA WAY SOUTH SAN FRANCISCO, CA 94080			ART UNIT	PAPER NUMBER
SOUTH SAN	FRANCISCO, CA 24000		1642	
			DATE MAILED: 08/18/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

,	
5	ذ

Advisory Action

Application No.	Applicant(s)	Applicant(s)	
09/723,703	BOTSTEIN ET AL.		
Examiner	Art Unit		
Larry R. Helms	1642		

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

	THE REPLY FILED 04 August 2004 FAILS TO PLACE THIS Therefore, further action by the applicant is required to avoid final rejection under 37 CFR 1.113 may only be either: (1) a ti condition for allowance; (2) a timely filed Notice of Appeal (wi Examination (RCE) in compliance with 37 CFR 1.114.	mely filed amendment which places the application in the appeal fee); or (3) a timely filed Request for Continued
	PERIOD FOR REPLY	([check either a) or b)]
	a) The period for reply expiresmonths from the mailing dat	e of the final rejection.
	the statuton, poriod for reply expire later	ory Action, or (2) the date set forth in the final rejection, whichever is later. In than SIX MONTHS from the mailing date of the final rejection. ED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP
	706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date fee have been filed is the date for purposes of determining the period of ext fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the s (2) as set forth in (b) above, if checked. Any reply received by the Office latitimely filed, may reduce any earned patent term adjustment. See 37 CFR	er than three months after the maining date of the main rejection, even in
	1. A Notice of Appeal was filed on <u>04 August 2004</u> . Appel 37 CFR 1.192(a), or any extension thereof (37 CFR 1.	lant's Brief must be filed within the period set forth in 191(d)), to avoid dismissal of the appeal.
l	2. The proposed amendment(s) will not be entered becau	use:
l	(a) ⊠ they raise new issues that would require further co	onsideration and/or search (see NOTE below);
	(b) ☐ they raise the issue of new matter (see Note below	w);
	issues for appeal; and/or	etter form for appeal by materially reducing or simplifying the
	(d) ☐ they present additional claims without canceling a	a corresponding number of finally rejected claims.
	NOTE: <u>See Continuation Sheet</u> .	
	3. Applicant's reply has overcome the following rejection	(s): <u>none</u> .
	canceling the non-allowable claim(s).	allowable if submitted in a separate, timely filed amendment
	5.⊠ The a) affidavit, b) exhibit, or c) request for recapplication in condition for allowance because: see ab	consideration has been considered but does NOT place the ove.
	6. The affidavit or exhibit will NOT be considered becaus raised by the Examiner in the final rejection.	e it is not directed SOLELY to issues which were newly
	7. For purposes of Appeal, the proposed amendment(s) explanation of how the new or amended claims would	a)⊠ will not be entered or b)⊡ will be entered and an I be rejected is provided below or appended.
	The status of the claim(s) is (or will be) as follows:	
	Claim(s) allowed: <u>none</u> .	
	Claim(s) objected to: <u>none</u> .	
	Claim(s) rejected: <u>1,3,24-29 and 31-41</u> .	
	Claim(s) withdrawn from consideration:	
	8. The drawing correction filed on is a) approv	ed or b)☐ disapproved by the Examiner.
	9. Note the attached Information Disclosure Statement(s	
	10. Other:	LARRY R. HELMS, PH.D
		LAURIT TRAINCIPPO //// / / / / / / MS PH.U

PRIMARY EXAMINER

Continuation Sheet (PTOL-303)

Continuation of 2. NOTE: the claims have been amended to recite a method of screening for higher expression of SEQ ID NO:1 or 2 with a nucleic acid of at least twenty nucleotides of SEQ ID NO:1 or 2. It is unclear if support is found for the probe and in addition a new search would have to be performed..

LARRY R. HELMS, PH.D PRIMARY EXAMINER